<DOC>
	<DOC>NCT01338415</DOC>
	<brief_summary>The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).</brief_summary>
	<brief_title>FUTURE 3 Study Extension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1. Patients who completed the FUTURE 3 core study (AC052373) or prematurely discontinued due to PAHprogression, if bosentan was not permanently discontinued 2. Patients who tolerated bosentan pediatric formulation and for whom bosentan is considered beneficial at the end of the FUTURE 3 core study (AC052373) 3. Signed informed consent by the parents or the legal representatives prior to any studymandated procedure. 1. Known intolerance or hypersensitivity to bosentan or any of the excipients of the dispersible bosentan tablet 2. Any clinically significant laboratory abnormality that precludes continuation of bosentan therapy 3. Pregnancy 4. AST and/or ALT values &gt; 3 times the upper limit of normal range (ULN) 5. Moderate to severe hepatic impairment, i.e., ChildPugh Class B or C 6. Premature and permanent study drug discontinuation during the FUTURE 3 core study (AC052373) 7. Any major violation of the FUTURE 3 core study (AC052373) protocol.</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pediatric</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>bosentan</keyword>
	<keyword>Tracleer</keyword>
</DOC>